ERBB2 and breast cancer: Despite the extensive variety of clinical trials supporting the efficacy and safety of the neoadjuvant use of pertuzumab, trastuzumab plus CT in HER2-positive BC, these studies often include highly selected patient populations which could not necessarily represent the general population with early-stage HER2-positive BC.